Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Exploration of MedicineOpen Access

Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens

View Full Paper
Ask AI
Bookmark
Share

Authors

AGApostolos P. GeorgopoulosLJLisa M James

Discussion

Loading...

Member takes

Overview

Review shows cancer immunotherapies boost immune reaction in solid tumors, suggesting a potential for novel treatments.

Key Points

  • Solid tumors can be targeted through a novel therapy focused on antigen incompatibility, promoting tumor rejection.
  • Incompatible antigen administration aims to activate an immune reaction against tumors, assuming the patient's immunocompetency.
  • Proposed therapy includes intra-tumor delivery of mRNA blueprints and anti-A/B/H antibodies that create local immune responses.
  • Further investigation is warranted to assess the effectiveness of this unique approach in cancer immunotherapies.

Cite This Study

Georgopoulos et al. (2025) studied this question.

synapsesocial.com/papers/692b9da91d383f2b2a37a41fhttps://doi.org/10.37349/emed.2025.1001375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy2026
  2. 2Generating Patient-Specific Anti-Tumor Responses with Non-Genetically Altered ‘Off-the-Shelf’ Allogeneic Cell Therapy: Leveraging Allo-Incompatibility for In Situ Vaccination2026
  3. 3Allogeneic Whole-Cell Immunotherapy: A Medical Hypothesis for Breaking Tumor Tolerance via Allo-reactivity and Intermolecular Epitope Spreading2016
  4. 4Humoral immunity in cancer2026
  5. 5Blood Type and Allergy-Assisted Cancer Immunotherapy2025